Lipid-mediated polynucleotide administration to reduce...

Details Lipid-mediated polynucleotide administration to reduce... Lipid-mediated polynucleotide administration to reduce...

2005-03-15

2005-03-15

Crouch, Deborah (Department: 1632)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

Reexamination Certificate

active

06867195

ABSTRACT:
A method for delivering an isolated polynucleotide to the interior of a cell in a vertebrate, comprising the interstitial introduction of an isolated polynucleotide into a tissue of the vertebrate where the polynucleotide is taken up by the cells of the tissue and exerts a therapeutic effect on the vertebrate. The method can be used to deliver a therapeutic polypeptide to the cells of the vertebrate, to provide an immune response upon in vivo translation of the polynucleotide, to deliver antisense polynucleotides, to deliver receptors to the cells of the vertebrate, or to provide transitory gene therapy.

REFERENCES:
patent: 3931397 (1976-01-01), Harnden
patent: 4224404 (1980-09-01), Viza
patent: 4394448 (1983-07-01), Szoka
patent: 4689320 (1987-08-01), Kaji
patent: 4699880 (1987-10-01), Goldstein
patent: 4704692 (1987-11-01), Ladner
patent: 4738927 (1988-04-01), Taniguchi et al.
patent: 4761375 (1988-08-01), Clark
patent: 4806463 (1989-02-01), Goodchild
patent: 4897355 (1990-01-01), Eppstein et al.
patent: 4945050 (1990-07-01), Sanford
patent: 4946787 (1990-08-01), Eppstein et al.
patent: 5049386 (1991-09-01), Eppstein et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5641665 (1997-06-01), Hobart et al.
patent: 5676954 (1997-10-01), Brigham
patent: 5693622 (1997-12-01), Wolff et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 6387395 (2002-05-01), Eppstein et al.
patent: 1 169 793 (1984-06-01), None
patent: 0 027 662 (1981-04-01), None
patent: 0187702 (1986-07-01), None
patent: 188574 (1986-07-01), None
patent: 7 781 (1970-03-01), None
patent: 63-285738 (1988-11-01), None
patent: 1047381 (1989-02-01), None
patent: 2135092 (1990-05-01), None
patent: 3102682 (1991-04-01), None
patent: WO 8600930 (1986-02-01), None
patent: WO-A-8805077 (1988-07-01), None
patent: 9001543 (1990-02-01), None
patent: WO 9107487 (1991-05-01), None
patent: WO 9116024 (1991-10-01), None
patent: WO 9719675 (1997-06-01), None
patent: WO 9737966 (1997-10-01), None
Yokoyama et al (1996) FEMS Immunol. Med. Microbiol. 14, 221-230.*
Gregoriadis et al (1997) FEBS Letts. 402, 107-110.*
Martinori et al (1993) Eu. J. Immunol. 23, 1719-1722.*
Bachmann et al (1994) Curr. Op. Immunol. 6, 320-326.*
Illustration Dictionary of Immunol., CRC Press, Inc. 1995.*
Vieweg et al (1995) Cancer Invest. 13, 193-201.*
Vieweg et al (1994) Cancer Res. 54.*
Robinson et al (1984) Science 225, 417-419.*
Wolff et al (1990) Science 247, 1465-1468.*
Partial English translation of Japanese Patent Application No. 63-285738.
Kikuchi, H. and Inoue, K., “Liposomes: Properties and Applications,”Yukagaku 34:784-798, Nihon Yushi Kagaku Kyokai (1985).
Kunitake, T., “Synthetic Bilayer Membranes—Self-Assembling Behavior of Organic Molecules,”Seibutsu Butsuri 21:289-301, Yoshiaka Shoten (1981).
Rupert, L.A.M., et al., “Fusogenic Behavior of Didodecyldimethylammonium Bromide Bilayer Vesicles,”J. Am. Chem. Soc. 107:2628-2631, American Chemical Society (1985).
Rustum, Y.M., et al., “Role of Liposome Type and Route of Administration in the Antitumor Activity of Liposome-entrapped 1-β-D-arabinofuranosylcytosine against Mouse L1210 Leukemia,”Canc. Res. 39:1390-1395, American Association for Cancer Research (1979).
Kunio, Y.,“Introduction of Gene into Cell,” Japanese Patent Abstract from esp@cenet database 12, English language abstract for Japanese Patent No. 2135092 (Document AN2).
Anker, P. et al. “Spontaneous Release of DNA by Human Blood Lymphocytes as Shown in an in Vitro System,”Cancer Res. 35:2375-2382 (1975).
Anker, P. et al. “The Role of Extracellular DNA in the Transfer of Information from T to B Human Lymphocytes in the Course of an Immune Response,”J. Immunogen.7:475-481 (1980).
Anker, P. et al. “Transfert d'information de lymphocytes T & B au cours d'une réponse, immune: rôle de l'ADN extracellulaire,”Schweiz med. Wschr. 110:1444-1446 (1980).
Anker, P. et al. “Nude Mice Injected with DNA Excreted by Antigen-Stimulated Human T Lymphocytes Synthesize Specific Human Antibodies,”Exp. Cell. Biol. 53:133-136 (1984).
Bains, W.Biotechnology from A to Z, 2nded.Oxford University Press, New York, NY pp. 17-19 (1998).
Chan, H.W. et al. “Molecular Cloning of Polyoma Virus DNA inEscherichia coli: Lambda Phage Vector System,”Science 203:887-892 (1979).
Clements-Mann, M.L. et al. “Safety and Immunogenicity of Influenza Hemagglutinin DNA Vaccine Alone or With Aluminum Adjuvant in Adult Volunteers,”American Soc. Virol. Annual Meeting(1997).
Cohen, J. “Naked DNA Points Way to Vaccines,”Science 259:1691-1692 (Mar. 1993).
Davey, J. et al., “Location of Influenza Virus M, NP, and NS1 Proteins in Microinjected Cells,”J. gen. Virol. 66:2319-2334 (1985).
Deck, R.R. et al. “Characterization of humoral immuno responses induced by an influenza hemagglutinin DNA vaccine,”Vaccine 15:71-78 (Jan. 1997).
DeNoto, F.M. et al. “Human growth hormone DNA sequence and mRNA structure: possible alternative splicing,”Nucl. Acids Res. 9:3719-3730 (1981).
Dixon, B. “The Third Vaccine Revolution,”Biotechnol. 13:420 (May 1995).
Donnelly, J.J. et al. “Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus,”Nat. Med. 1:583-597 (Jun. 1995).
Fainboim, L. et al., “Transfer of experimental allergic orchitis with immune RNA. Studies in vivo,”Clin. exp. Immunol. 34:92-99 (1978).
Feitelson, M.A. et al. “A Chronic Carrierlike State Is Established in Nude Mice Injected with Cloned Hepatitis B Virus DNA,”J. Virol. 62:1408-1415 (1988).
Fields, B.N. et al.,Eds., Fields Virology 2nded., Raven Press, New York, pp. 1596-1614 (1989).
Gélinas, C. et al. “Tumorigenic activity of cloned polyoma virus DNA in newborn rats,”Experientia 37:1074-1075 (1981).
Gorman, C.M. et al. “Recombinant Genomes Which Express Chloramphenicol Acetyltransferase in Mammalian Cells,”Mol. Cell. Biol. 2:1044-1051 (1982).
Gorman, C.M. et al. “The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection,”Proc. Natl. Acad. Sci. USA 79:6777-6781 (1982).
Goldman, C.K. et al. “In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer,”Nat. Biotech. 15:462-466 (May 1997).
Hardman, J.G. et al.Eds., Goodman&Gilman's The Pharmacological Basis of Therapeutics. 9thed., McGraw-Hill, p. 8 (1996).
Israel, M.A. et al. “Molecular Cloning of Polyoma Virus DNA inEscherichia coli: Plasmid Vector System,”Science 203:883-887 (1979).
Israel, M.A. et al. “Biological Activity of Polyoma Viral DNA in Mice and Hamsters,”J. Virol. 29:990-996 (1979).
Jacherts, D. and Drescher, J. “Antibody Response in Rhesus Monkeys and Guinea Pigs to Inoculation with RNA Derived from Antigenetically Stimulated Cell-Free Systems,”J. Immunol. 104:746-752 (1970).
Jachertz, D. and Egger, M. “Treatment of P815 Mastocytoma in DBA/2 Mice with RNA,”J. Immunogen. 1:355-362 (1974).
Jachertz, D. et al. “Information carried by the DNA released by antigen-stimulated lymphocytes,”Immunol. 37:753-763 (1979).
Jiao, S. et al., “Direct Gene Transfer into Nonhuman Primate Myofibers In Vivo,”Hum. Gen. Ther. 3:21-33 (Feb. 1992).
Krieg, A.M. et al. “Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs,”Proc. Natl. Acad. Sci. USA 95:12631-12636 (Oct. 1998).
Kruczek, I. and Doerfler, W. “Expression of the chloramphenicol acetyltransferase gene in mammalian cells under the control of adenovirus type 12 promoters: Effect of promoter methylation on gene expression,”Proc. Natl. Acad. Sci. USA 80:7586-7590 (1983).
Laub, O. et al. “Sy

Affiliated with

Also associated with

Rating

Lipid-mediated polynucleotide administration to reduce... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lipid-mediated polynucleotide administration to reduce..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipid-mediated polynucleotide administration to reduce... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3389957